hyoscyamine has been researched along with caffeic acid in 1 studies
| Studies (hyoscyamine) | Trials (hyoscyamine) | Recent Studies (post-2010) (hyoscyamine) | Studies (caffeic acid) | Trials (caffeic acid) | Recent Studies (post-2010) (caffeic acid) |
|---|---|---|---|---|---|
| 99 | 1 | 55 | 2,074 | 15 | 1,187 |
| Protein | Taxonomy | hyoscyamine (IC50) | caffeic acid (IC50) |
|---|---|---|---|
| RNA polymerase beta subunit (EC 2.7.7.6), partial | Escherichia coli | 23.7759 | |
| Lipoxygenase | Solanum tuberosum (potato) | 3.5 | |
| Interstitial collagenase | Homo sapiens (human) | 0.2389 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 3 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 3 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.0243 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 8.5 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.0156 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.06 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 3.37 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.1246 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3 | |
| Integrase | Human immunodeficiency virus 1 | 2.8 | |
| large T antigen | Betapolyomavirus macacae | 7.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
1 other study(ies) available for hyoscyamine and caffeic acid
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |